130 related articles for article (PubMed ID: 28169130)
1. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
Bouchard P; Chabbert-Buffet N
Best Pract Res Clin Obstet Gynaecol; 2017 Apr; 40():105-110. PubMed ID: 28169130
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
3. Long-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequences.
Olejek A; Olszak-Wąsik K; Czerwinska-Bednarska A
Prz Menopauzalny; 2016 Mar; 15(1):48-51. PubMed ID: 27095959
[TBL] [Abstract][Full Text] [Related]
4. The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
Westhoff CL; Guo H; Wang Z; Hibshoosh H; Polaneczky M; Pike MC; Ha R
Breast Cancer Res Treat; 2022 Apr; 192(2):321-329. PubMed ID: 35015210
[TBL] [Abstract][Full Text] [Related]
5. 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies.
Critchley HOD; Chodankar RR
J Mol Endocrinol; 2020 Jul; 65(1):T15-T33. PubMed ID: 32599565
[TBL] [Abstract][Full Text] [Related]
6. Relugolix+estradiol+norethisterone for symptomatic uterine fibroids.
Aust Prescr; 2024 Apr; 47(2):68-69. PubMed ID: 38737374
[No Abstract] [Full Text] [Related]
7. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
8. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
10. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Lee MJ; Yun BS; Seong SJ; Kim ML; Jung YW; Kim MK; Bae HS; Kim DH; Hwang JY
Obstet Gynecol Sci; 2017 Jan; 60(1):69-73. PubMed ID: 28217674
[TBL] [Abstract][Full Text] [Related]
11. Endometrial changes during ulipristal acetate use: A systematic review.
De Milliano I; Van Hattum D; Ket JCF; Huirne JAF; Hehenkamp WJK
Eur J Obstet Gynecol Reprod Biol; 2017 Jul; 214():56-64. PubMed ID: 28482329
[TBL] [Abstract][Full Text] [Related]
12. Heavy menstrual bleeding: An update on management.
Davies J; Kadir RA
Thromb Res; 2017 Mar; 151 Suppl 1():S70-S77. PubMed ID: 28262240
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C; Bumbuliene Ž; Costa AR; Heikinheimo O; Heweker A; Hudeček R; Jacquemyn Y; Melis GB; Parashar P; Rechberger T; Sánchez AC; van Aken B; Zatik J; Gemzell-Danielsson K
Contemp Clin Trials; 2017 Apr; 55():56-62. PubMed ID: 28185997
[TBL] [Abstract][Full Text] [Related]
14. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
15. An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome.
Chen BF; Powell MC; O'Beirne C
J Obstet Gynaecol; 2017 Jul; 37(5):645-648. PubMed ID: 28498002
[TBL] [Abstract][Full Text] [Related]
16. Update on medical treatment of uterine fibroids.
Faustino F; Martinho M; Reis J; Águas F
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():61-68. PubMed ID: 28732252
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis.
de Milliano I; Twisk M; Ket JC; Huirne JA; Hehenkamp WJ
PLoS One; 2017; 12(10):e0186158. PubMed ID: 29036173
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France.
Fernandez H; Jourdain O; Villefranque V; Lehmann M; Lafuma A; Trancart M
BMJ Open; 2017 Sep; 7(9):e015571. PubMed ID: 28871011
[TBL] [Abstract][Full Text] [Related]
19. Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy?
Luketic L; Shirreff L; Kives S; Liu G; El Sugy R; Leyland N; Solnik MJ; Murji A
J Minim Invasive Gynecol; 2017; 24(5):797-802. PubMed ID: 28351762
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
